- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01699152
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
July 23, 2019 updated by: Tragara Pharmaceuticals, Inc.
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is a multi-center, open-label, dose escalation study.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The primary objective is to determine the highest dose of TG02 citrate that can be safely given to patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- GRU
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- DFCI
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- OSU
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- SCRI
-
-
Texas
-
Houston, Texas, United States, 77030
- MDACC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have histologically confirmed Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma.
Patients must meet one or more of the following indications for treatment:
- Progressive disease or marked splenomegaly and/or lymphadenopathy.
- Anemia (hemoglobin <11 mg/dL) or thrombocytopenia (platelets<100,000/μL).
- Unexplained weight loss exceeding 10% of body weight over the previous 6 months.
- CTCAE Grade 2 or 3 fatigue.
- Fevers >100.5º F or night sweats for more than 2 weeks without evidence of infection.
- Progressive lymphocytosis, with an increase exceeding 50% over a 2 month period or a doubling time of less than 6 months.
- Need for cytoreduction prior to allogeneic stem cell transplant.
- Patients must have relapsed or refractory disease after ≥1 prior line of treatment.
- The interval from prior treatment to time of study drug administration should be at least 5 half-lives for cytotoxic and noncytotoxic agents.
- Low-dose corticosteroids (prednisone <20 mg/ day or equivalent dose) are permitted throughout study.
- Clinically significant toxicities from prior chemotherapy must be resolved to Grade ≤ 1.
- Age >18 years.
- ECOG performance status ≤2.
- Life expectancy ≥ 12 weeks.
Patients must have normal organ and marrow function as defined below:
- absolute neutrophil count >1,000/μL in absence of bone marrow involvement
- platelets ≥30,000/μL in absence of bone marrow involvement
- If patient has extensive bone marrow involvement, minimum ANC and platelet levels are not required.
- total bilirubin ≤1.5 X institutional ULN unless due to Gilbert's syndrome, controlled autoimmune hemolytic anemia or immune thrombocytopenia
- AST(SGOT)/ALT(SGPT) <2.5 X institutional ULN unless due to disease
- creatinine <2.0 mg/dL OR creatinine clearance >50 mL/min/1.73 m2
- Negative serum or urine pregnancy test at the time of first dose for WOCBP.
- Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for required assessments.
- Ability to take oral medication.
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (CTCAE Grade > 1) due to agents administered more than 3 weeks earlier.
- Patients who have received prior treatment with a CDK inhibitor within 12 months of study enrollment.
- High-dose corticosteroids (prednisone ≥20mg/day or equivalent dose) must be discontinued ≥ 7 days of initiating therapy.
- Patients with known central nervous system involvement.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition as TG02 citrate.
- Patients with G6PD deficiency.
- Concurrent severe or uncontrolled medical disease (including but not limited to history of ventricular arrhythmia or symptomatic conduction abnormality within 12 months, ongoing or active systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
- Pregnant and/or breast-feeding women.
- Prior or second malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical or breast cancer, or other cancer for which the subject has received curative therapy at least 3 years prior to study entry.
- Known HIV or AIDs.
- QTc interval prolongation >450ms for males and >470 ms for females.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TG02 citrate
TG02 citrate capsules given orally.
|
TG02 citrate capsules
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose
Time Frame: 28 days
|
To assess the number of patients with dose-limiting toxicities (DLT) and the dose of TG02 citrate that can be safely given to patients with CLL or SLL.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 28 days
|
The number of patients with adverse events
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: T Parrott, Tragara Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Actual)
July 1, 2015
Study Completion (Actual)
May 1, 2016
Study Registration Dates
First Submitted
October 1, 2012
First Submitted That Met QC Criteria
October 1, 2012
First Posted (Estimate)
October 3, 2012
Study Record Updates
Last Update Posted (Actual)
July 25, 2019
Last Update Submitted That Met QC Criteria
July 23, 2019
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TG02-102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)TerminatedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedLeukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Celgene CorporationTerminatedChronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteWithdrawnRefractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditionsUnited States
Clinical Trials on TG02 citrate
-
Lee's Pharmaceutical LimitedChina Oncology Focus LimitedWithdrawnHepatocellular Carcinoma
-
National Cancer Institute (NCI)CompletedGlioblastoma | Astrocytoma | Brain Tumor | Gliosarcoma | AstrogliomaUnited States
-
Lee's Pharmaceutical LimitedUnknown
-
Targovax ASATerminated
-
European Organisation for Research and Treatment...Tragara Pharmaceuticals, Inc.CompletedGlioblastoma | Astrocytoma, Grade IIIFrance, Austria, Germany, Netherlands, Switzerland
-
Tragara Pharmaceuticals, Inc.CompletedMultiple Myeloma | AML | Blast Crisis | MDS | ALLUnited States
-
OSF Healthcare SystemRecruitingRestless Legs SyndromeUnited States
-
The Seventh Affiliated Hospital, Southern Medical...Completed
-
Peking Union Medical College HospitalCompletedCritical Illness | Coagulation; Intravascular | Kidney Replacement DisorderChina
-
Vanderbilt University Medical CenterTerminated